Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer

The purpose of this clinical trial is to determine whether using chemotherapy followed by stereotactic ablative body radiation therapy (SABR) and tumor treating fields (TTF) will slow tumor growth in people with locally advanced pancreas cancer. All participants will receive SABR therapy once per day for five days and use the TTF system for at least 18 hours per day starting on the first day of SABR until the tumor progresses or severe toxicity develops.

NCT Number	NCT05679674
Lead Sponsor	Baptist Health South Florida Collaborators: NovoCure Ltd.
Conditions	Pancreas Cancer, Locally Advanced, Locally Advanced Pancreatic Adenocarcinoma
Enrollment	48 participants
Start Date	2023-09-21
Primary Completion	2027-06 (estimated)
Study Completion	2027-06 (estimated)
Updated on ClinicalTrials.gov	2026-01-12